losartan has been researched along with Cockayne-Touraine Disease in 6 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of losartan in the prevention of restenosis after BD of esophageal stenosis in children with DEB." | 8.31 | Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa. ( Abaykhanov, R; Budkina, T; Dyakonova, E; Fisenko, A; Gusev, A; Lokhmatov, M; Murashkin, N; Oldakovskiy, V; Tupylenko, A; Yatzik, S, 2023) |
| "To evaluate the efficacy of losartan in the prevention of restenosis after BD of esophageal stenosis in children with DEB." | 4.31 | Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa. ( Abaykhanov, R; Budkina, T; Dyakonova, E; Fisenko, A; Gusev, A; Lokhmatov, M; Murashkin, N; Oldakovskiy, V; Tupylenko, A; Yatzik, S, 2023) |
| "The scarring is driven by inflammatory processes, particularly the TGF-β signaling pathways, resulting in excess synthesis and deposition of the extracellular matrix, especially collagen." | 1.72 | Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series. ( Abdollahimajd, F; Hajimoradi, B; Mansouri, P; Pourani, MR; Rakhshan, A; Uitto, J; Vahidnezhad, H; Youssefian, L, 2022) |
| "A 6-year-old child with recessive dystrophic epidermolysis bullosa, confirmed by history, clinical exam, and antigen mapping, was treated with losartan with reduction in the blistering and better quality of life." | 1.56 | Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa. ( Inamadar, AC, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pourani, MR | 1 |
| Vahidnezhad, H | 2 |
| Mansouri, P | 1 |
| Youssefian, L | 1 |
| Rakhshan, A | 1 |
| Hajimoradi, B | 1 |
| Abdollahimajd, F | 1 |
| Uitto, J | 2 |
| Relvas, M | 1 |
| Figueiredo, AC | 1 |
| Calado, R | 1 |
| Calvão, J | 1 |
| Ramos, L | 1 |
| Oldakovskiy, V | 1 |
| Murashkin, N | 1 |
| Lokhmatov, M | 1 |
| Gusev, A | 1 |
| Tupylenko, A | 1 |
| Budkina, T | 1 |
| Yatzik, S | 1 |
| Dyakonova, E | 1 |
| Abaykhanov, R | 1 |
| Fisenko, A | 1 |
| Inamadar, AC | 1 |
| Nyström, A | 1 |
| Thriene, K | 1 |
| Mittapalli, V | 1 |
| Kern, JS | 1 |
| Kiritsi, D | 1 |
| Dengjel, J | 1 |
| Bruckner-Tuderman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Computational Drug Repurposing for All Epidermolysis Bullosa Simplex (EBS) Cases[NCT03269474] | 60 participants (Anticipated) | Observational | 2017-11-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for losartan and Cockayne-Touraine Disease
| Article | Year |
|---|---|
Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series.
Topics: Animals; Cicatrix; Collagen; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Female; Losartan; | 2022 |
Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases.
Topics: Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Humans; Losartan; Skin | 2022 |
Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa.
Topics: Adolescent; Child; Child, Preschool; Constriction, Pathologic; Epidermolysis Bullosa; Epidermolysis | 2023 |
Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa.
Topics: Child; Epidermolysis Bullosa Dystrophica; Humans; Losartan; Quality of Life | 2020 |
Losartan for treatment of epidermolysis bullosa: A new perspective.
Topics: Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Humans; Losartan | 2021 |
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.
Topics: Animals; Disease Models, Animal; Epidermolysis Bullosa Dystrophica; Immunologic Factors; Inflammatio | 2015 |